目的观察阿格拉宾在小鼠肺缺血再灌注损伤中的作用并探讨可能机制。方法根据随机数表法将40只8~10周龄雄性C57/B6小鼠随机分为4组,即对照组、阿格拉宾组、缺血再灌注组和治疗组。采用左肺门夹闭1h,再灌注2h的方式构建小鼠肺缺血再灌注...目的观察阿格拉宾在小鼠肺缺血再灌注损伤中的作用并探讨可能机制。方法根据随机数表法将40只8~10周龄雄性C57/B6小鼠随机分为4组,即对照组、阿格拉宾组、缺血再灌注组和治疗组。采用左肺门夹闭1h,再灌注2h的方式构建小鼠肺缺血再灌注损伤模型,治疗组小鼠在肺门夹闭前1h给予阿格拉宾(5μg/kg)腹腔注射。再灌注结束后,留取左肺组织行HE染色评估肺损伤状况,同时Western blot法检测炎性因子[白细胞介素-1β(interleukin-1β,IL-1β),单核细胞趋化因子-1(monocyte chemoattractant protein-1,MCP-1),肿瘤坏死因子(tumor necrosis factor,TNF)-α]、焦亡标志物[NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor thermal protein domain associated protein 3,NLRP3)和凋亡相关斑点样蛋白(apoptosis-associated speck-like protein containing a caspase-recruitment domain,ASC)]及自噬相关蛋白(Beclin1和ATG7)的表达。结果缺血再灌注组较对照组小鼠肺组织病理损伤明显加重,肺组织炎性因子IL-1β、MCP-1和TNF-α相对表达明显升高(P均<0.05),焦亡相关标志蛋白NLPR3和ASC的表达水平明显升高(P均<0.05),同时自噬相关蛋白Beclin1和ATG7被明显抑制(P均<0.05);予以阿格拉宾预处理后,肺缺血再灌注小鼠肺病理损伤明显减轻、肺组织炎性因子IL-1β、MCP-1和TNF-α相对表达明显降低(P均<0.05);焦亡相关标志蛋白NLPR3和ASC的表达水平明显降低(P均<0.05),自噬相关蛋白Beclin-1和ATG7被明显上调(P均<0.05)。结论阿格拉宾可能通过抑制焦亡并激活自噬改善小鼠肺缺血再灌注损伤。展开更多
The mandatory preclinical safety evaluation is an essential prerequisite to obtain the qualitative and effective medicines. Due to the fact that drugs may reveal genotoxic properties, the investigation of their mutage...The mandatory preclinical safety evaluation is an essential prerequisite to obtain the qualitative and effective medicines. Due to the fact that drugs may reveal genotoxic properties, the investigation of their mutagenic activity is an obligatory part of the preclinical drug safety program. The aim of the research is to study mutagenic properties of a new original immunomodulator Arglabin native in tablets in the induced test of gene mutations （the Ames test） on Salmonella typhimurium strains. Materials and methods： Four strains of S. typhimurium TA98, TA100, TA1535, and TA1537 were used to assess the mutagenicity in the Ames test. Results and conclusions： No statistically reliable dose-dependent increase in the number of revertant colonies of Salmonella typhimurium has been observed in the presence of the given drug within the investigated dose ranges from 5.0 to 100.0 μg/mL for strains TA100 and TA1535, and from 5.0 to 250 μg/mL for strains TA98 and TA1537 against the baseline of spantaneous mutations. Arglabin native in tablets does not reveal a mutagenic activity within the studied dose ranges on Salmonella typhimurium strains TA98, TA100, TA1535, TA1537.展开更多
文摘目的观察阿格拉宾在小鼠肺缺血再灌注损伤中的作用并探讨可能机制。方法根据随机数表法将40只8~10周龄雄性C57/B6小鼠随机分为4组,即对照组、阿格拉宾组、缺血再灌注组和治疗组。采用左肺门夹闭1h,再灌注2h的方式构建小鼠肺缺血再灌注损伤模型,治疗组小鼠在肺门夹闭前1h给予阿格拉宾(5μg/kg)腹腔注射。再灌注结束后,留取左肺组织行HE染色评估肺损伤状况,同时Western blot法检测炎性因子[白细胞介素-1β(interleukin-1β,IL-1β),单核细胞趋化因子-1(monocyte chemoattractant protein-1,MCP-1),肿瘤坏死因子(tumor necrosis factor,TNF)-α]、焦亡标志物[NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor thermal protein domain associated protein 3,NLRP3)和凋亡相关斑点样蛋白(apoptosis-associated speck-like protein containing a caspase-recruitment domain,ASC)]及自噬相关蛋白(Beclin1和ATG7)的表达。结果缺血再灌注组较对照组小鼠肺组织病理损伤明显加重,肺组织炎性因子IL-1β、MCP-1和TNF-α相对表达明显升高(P均<0.05),焦亡相关标志蛋白NLPR3和ASC的表达水平明显升高(P均<0.05),同时自噬相关蛋白Beclin1和ATG7被明显抑制(P均<0.05);予以阿格拉宾预处理后,肺缺血再灌注小鼠肺病理损伤明显减轻、肺组织炎性因子IL-1β、MCP-1和TNF-α相对表达明显降低(P均<0.05);焦亡相关标志蛋白NLPR3和ASC的表达水平明显降低(P均<0.05),自噬相关蛋白Beclin-1和ATG7被明显上调(P均<0.05)。结论阿格拉宾可能通过抑制焦亡并激活自噬改善小鼠肺缺血再灌注损伤。
文摘The mandatory preclinical safety evaluation is an essential prerequisite to obtain the qualitative and effective medicines. Due to the fact that drugs may reveal genotoxic properties, the investigation of their mutagenic activity is an obligatory part of the preclinical drug safety program. The aim of the research is to study mutagenic properties of a new original immunomodulator Arglabin native in tablets in the induced test of gene mutations （the Ames test） on Salmonella typhimurium strains. Materials and methods： Four strains of S. typhimurium TA98, TA100, TA1535, and TA1537 were used to assess the mutagenicity in the Ames test. Results and conclusions： No statistically reliable dose-dependent increase in the number of revertant colonies of Salmonella typhimurium has been observed in the presence of the given drug within the investigated dose ranges from 5.0 to 100.0 μg/mL for strains TA100 and TA1535, and from 5.0 to 250 μg/mL for strains TA98 and TA1537 against the baseline of spantaneous mutations. Arglabin native in tablets does not reveal a mutagenic activity within the studied dose ranges on Salmonella typhimurium strains TA98, TA100, TA1535, TA1537.
